FCHSD2

Across TCGA pan-cancer cohorts, FCHSD2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FCHSD2 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FCHSD2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FCHSD2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where FCHSD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	II,III,IV	0.902	0.246	<.001	38	view →
LUAD	DFS	Quartile	All	0.888	0.506	<.001	28	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	3	view →
HNSC	OS	Median	III,IV	1.000	0.946	.037	2	view →
LSCC	OS	Tertile	II,III,IV	0.596	0.890	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FCHSD2–CCRCC (DFS)

Open the CCRCC breakdown →